The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis.
Smorenburg
S M
SM
Vink
R
R
Otten
H M
HM
Swaneveld
F
F
Büller
H R
HR
D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality; D000925:Anticoagulants / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000401:mortality; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000401:mortality; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality; D009369:Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000401:mortality*; D016017:Odds Ratio; D019851:Thrombophilia / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D014812:Vitamin K; D006493:Heparin